Cargando…
HIV-2/SIV Vpx antagonises NF-κB activation by targeting p65
BACKGROUND: The NF-κB family of transcription factors and associated signalling pathways are abundant and ubiquitous in human immune responses. Activation of NF-κB transcription factors by viral pathogen-associated molecular patterns, such as viral RNA and DNA, is fundamental to anti-viral innate im...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785589/ https://www.ncbi.nlm.nih.gov/pubmed/35073912 http://dx.doi.org/10.1186/s12977-021-00586-w |
_version_ | 1784638994434228224 |
---|---|
author | Fink, Douglas L. Cai, James Whelan, Matthew V. X. Monit, Christopher Maluquer de Motes, Carlos Towers, Greg J. Sumner, Rebecca P. |
author_facet | Fink, Douglas L. Cai, James Whelan, Matthew V. X. Monit, Christopher Maluquer de Motes, Carlos Towers, Greg J. Sumner, Rebecca P. |
author_sort | Fink, Douglas L. |
collection | PubMed |
description | BACKGROUND: The NF-κB family of transcription factors and associated signalling pathways are abundant and ubiquitous in human immune responses. Activation of NF-κB transcription factors by viral pathogen-associated molecular patterns, such as viral RNA and DNA, is fundamental to anti-viral innate immune defences and pro-inflammatory cytokine production that steers adaptive immune responses. Diverse non-viral stimuli, such as lipopolysaccharide and cytokines, also activate NF-κB and the same anti-pathogen gene networks. Viruses adapted to human cells often encode multiple proteins targeting the NF-κB pathway to mitigate the anti-viral effects of NF-κB-dependent host immunity. RESULTS: In this study we have demonstrated using a variety of assays, in a number of different cell types including primary cells, that plasmid-encoded or virus-delivered simian immunodeficiency virus (SIV) accessory protein Vpx is a broad antagonist of NF-κB signalling active against diverse innate NF-κB agonists. Using targeted Vpx mutagenesis, we showed that this novel Vpx phenotype is independent of known Vpx cofactor DCAF1 and other cellular binding partners, including SAMHD1, STING and the HUSH complex. We found that Vpx co-immunoprecipitated with canonical NF-κB transcription factor p65, but not NF-κB family members p50 or p100, preventing nuclear translocation of p65. We found that broad antagonism of NF-κB activation by Vpx was conserved across distantly related lentiviruses as well as for Vpr from SIV Mona monkey (SIVmon), which has Vpx-like SAMHD1-degradation activity. CONCLUSIONS: We have discovered a novel mechanism by which lentiviruses antagonise NF-κB activation by targeting p65. These findings extend our knowledge of how lentiviruses manipulate universal regulators of immunity to avoid the anti-viral sequelae of pro-inflammatory gene expression stimulated by both viral and extra-viral agonists. Importantly our findings are also relevant to the gene therapy field where virus-like particle associated Vpx is routinely used to enhance vector transduction through antagonism of SAMHD1, and perhaps also through manipulation of NF-κB. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12977-021-00586-w. |
format | Online Article Text |
id | pubmed-8785589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87855892022-01-24 HIV-2/SIV Vpx antagonises NF-κB activation by targeting p65 Fink, Douglas L. Cai, James Whelan, Matthew V. X. Monit, Christopher Maluquer de Motes, Carlos Towers, Greg J. Sumner, Rebecca P. Retrovirology Research BACKGROUND: The NF-κB family of transcription factors and associated signalling pathways are abundant and ubiquitous in human immune responses. Activation of NF-κB transcription factors by viral pathogen-associated molecular patterns, such as viral RNA and DNA, is fundamental to anti-viral innate immune defences and pro-inflammatory cytokine production that steers adaptive immune responses. Diverse non-viral stimuli, such as lipopolysaccharide and cytokines, also activate NF-κB and the same anti-pathogen gene networks. Viruses adapted to human cells often encode multiple proteins targeting the NF-κB pathway to mitigate the anti-viral effects of NF-κB-dependent host immunity. RESULTS: In this study we have demonstrated using a variety of assays, in a number of different cell types including primary cells, that plasmid-encoded or virus-delivered simian immunodeficiency virus (SIV) accessory protein Vpx is a broad antagonist of NF-κB signalling active against diverse innate NF-κB agonists. Using targeted Vpx mutagenesis, we showed that this novel Vpx phenotype is independent of known Vpx cofactor DCAF1 and other cellular binding partners, including SAMHD1, STING and the HUSH complex. We found that Vpx co-immunoprecipitated with canonical NF-κB transcription factor p65, but not NF-κB family members p50 or p100, preventing nuclear translocation of p65. We found that broad antagonism of NF-κB activation by Vpx was conserved across distantly related lentiviruses as well as for Vpr from SIV Mona monkey (SIVmon), which has Vpx-like SAMHD1-degradation activity. CONCLUSIONS: We have discovered a novel mechanism by which lentiviruses antagonise NF-κB activation by targeting p65. These findings extend our knowledge of how lentiviruses manipulate universal regulators of immunity to avoid the anti-viral sequelae of pro-inflammatory gene expression stimulated by both viral and extra-viral agonists. Importantly our findings are also relevant to the gene therapy field where virus-like particle associated Vpx is routinely used to enhance vector transduction through antagonism of SAMHD1, and perhaps also through manipulation of NF-κB. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12977-021-00586-w. BioMed Central 2022-01-24 /pmc/articles/PMC8785589/ /pubmed/35073912 http://dx.doi.org/10.1186/s12977-021-00586-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Fink, Douglas L. Cai, James Whelan, Matthew V. X. Monit, Christopher Maluquer de Motes, Carlos Towers, Greg J. Sumner, Rebecca P. HIV-2/SIV Vpx antagonises NF-κB activation by targeting p65 |
title | HIV-2/SIV Vpx antagonises NF-κB activation by targeting p65 |
title_full | HIV-2/SIV Vpx antagonises NF-κB activation by targeting p65 |
title_fullStr | HIV-2/SIV Vpx antagonises NF-κB activation by targeting p65 |
title_full_unstemmed | HIV-2/SIV Vpx antagonises NF-κB activation by targeting p65 |
title_short | HIV-2/SIV Vpx antagonises NF-κB activation by targeting p65 |
title_sort | hiv-2/siv vpx antagonises nf-κb activation by targeting p65 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785589/ https://www.ncbi.nlm.nih.gov/pubmed/35073912 http://dx.doi.org/10.1186/s12977-021-00586-w |
work_keys_str_mv | AT finkdouglasl hiv2sivvpxantagonisesnfkbactivationbytargetingp65 AT caijames hiv2sivvpxantagonisesnfkbactivationbytargetingp65 AT whelanmatthewvx hiv2sivvpxantagonisesnfkbactivationbytargetingp65 AT monitchristopher hiv2sivvpxantagonisesnfkbactivationbytargetingp65 AT maluquerdemotescarlos hiv2sivvpxantagonisesnfkbactivationbytargetingp65 AT towersgregj hiv2sivvpxantagonisesnfkbactivationbytargetingp65 AT sumnerrebeccap hiv2sivvpxantagonisesnfkbactivationbytargetingp65 |